메뉴 건너뛰기




Volumn 2, Issue 11, 2014, Pages 911-922

Combating the dual burden: Therapeutic targeting of common pathways in obesity and type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LEPTIN; LORCASERIN; NALTREXONE; PEPTIDE DERIVATIVE; PEPTIDE HORMONE; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SYNTHETIC PEPTIDE; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCOSE BLOOD LEVEL;

EID: 84901849274     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70004-X     Document Type: Review
Times cited : (169)

References (113)
  • 1
    • 80052245888 scopus 로고    scopus 로고
    • Health and economic burden of the projected obesity trends in the USA and the UK
    • Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011, 378:815-825.
    • (2011) Lancet , vol.378 , pp. 815-825
    • Wang, Y.C.1    McPherson, K.2    Marsh, T.3    Gortmaker, S.L.4    Brown, M.5
  • 2
    • 84858702540 scopus 로고    scopus 로고
    • The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives
    • Chen L, Magliano DJ, Zimmet PZ The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2012, 8:228-236.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 228-236
    • Chen, L.1    Magliano, D.J.2    Zimmet, P.Z.3
  • 3
    • 80052203917 scopus 로고    scopus 로고
    • Quantification of the effect of energy imbalance on bodyweight
    • Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011, 378:826-837.
    • (2011) Lancet , vol.378 , pp. 826-837
    • Hall, K.D.1    Sacks, G.2    Chandramohan, D.3
  • 4
    • 33845881411 scopus 로고    scopus 로고
    • Mechanisms linking obesity to insulin resistance and type 2 diabetes
    • Kahn SE, Hull RL, Utzschneider KM Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
    • (2006) Nature , vol.444 , pp. 840-846
    • Kahn, S.E.1    Hull, R.L.2    Utzschneider, K.M.3
  • 5
    • 84867487909 scopus 로고    scopus 로고
    • Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies
    • Bays HE Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol 2012, 110(suppl):4B-12B.
    • (2012) Am J Cardiol , vol.110 , pp. 4B-12B
    • Bays, H.E.1
  • 6
    • 33845914986 scopus 로고    scopus 로고
    • Mechanisms linking obesity with cardiovascular disease
    • Van Gaal LF, Mertens IL, De Block CE Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
    • (2006) Nature , vol.444 , pp. 875-880
    • Van Gaal, L.F.1    Mertens, I.L.2    De Block, C.E.3
  • 10
    • 79960262492 scopus 로고    scopus 로고
    • Management of type 2 diabetes: new and future developments in treatment
    • Tahrani AA, Bailey CJ, Del Prato S, Barnett AH Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
    • (2011) Lancet , vol.378 , pp. 182-197
    • Tahrani, A.A.1    Bailey, C.J.2    Del Prato, S.3    Barnett, A.H.4
  • 11
    • 77954351422 scopus 로고    scopus 로고
    • Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay
    • Niswender K Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obes Metab 2010, 12:267-287.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 267-287
    • Niswender, K.1
  • 13
    • 64649104158 scopus 로고    scopus 로고
    • Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo RA Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • DeFronzo, R.A.1
  • 14
    • 70449517253 scopus 로고    scopus 로고
    • 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
    • the Diabetes Prevention Program Research Group
    • Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. the Diabetes Prevention Program Research Group.
    • (2009) Lancet , vol.374 , pp. 1677-1686
    • Knowler, W.C.1    Fowler, S.E.2    Hamman, R.F.3
  • 15
    • 33751366229 scopus 로고    scopus 로고
    • Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study
    • Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679. the Finnish Diabetes Prevention Study Group.
    • (2006) Lancet , vol.368 , pp. 1673-1679
    • Lindström, J.1    Ilanne-Parikka, P.2    Peltonen, M.3
  • 16
    • 84880323061 scopus 로고    scopus 로고
    • Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
    • the Look AHEAD Research Group
    • Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154. the Look AHEAD Research Group.
    • (2013) N Engl J Med , vol.369 , pp. 145-154
    • Wing, R.R.1    Bolin, P.2    Brancati, F.L.3
  • 17
    • 0023205573 scopus 로고
    • Type II diabetic subjects lose less weight than their overweight nondiabetic spouses
    • Wing RR, Marcus MD, Epstein LH, Salata R Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987, 10:563-566.
    • (1987) Diabetes Care , vol.10 , pp. 563-566
    • Wing, R.R.1    Marcus, M.D.2    Epstein, L.H.3    Salata, R.4
  • 18
    • 84861578272 scopus 로고    scopus 로고
    • Less fat reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals completing a very-low-calorie diet program
    • Baker ST, Jerums G, Prendergast LA, Panagiotopoulos S, Strauss BJ, Proietto J Less fat reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals completing a very-low-calorie diet program. Metabolism 2012, 61:873-882.
    • (2012) Metabolism , vol.61 , pp. 873-882
    • Baker, S.T.1    Jerums, G.2    Prendergast, L.A.3    Panagiotopoulos, S.4    Strauss, B.J.5    Proietto, J.6
  • 19
    • 0038575814 scopus 로고    scopus 로고
    • Current management strategies for coexisting diabetes mellitus and obesity
    • Scheen AJ Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003, 63:1165-1184.
    • (2003) Drugs , vol.63 , pp. 1165-1184
    • Scheen, A.J.1
  • 20
    • 36448968168 scopus 로고    scopus 로고
    • Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
    • Hermansen K, Mortensen LS Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142.
    • (2007) Drug Saf , vol.30 , pp. 1127-1142
    • Hermansen, K.1    Mortensen, L.S.2
  • 21
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
    • (2012) Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 22
    • 34547161425 scopus 로고    scopus 로고
    • A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies
    • Barnett A, Allsworth J, Jameson K, Mann R A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007, 23:1493-1507.
    • (2007) Curr Med Res Opin , vol.23 , pp. 1493-1507
    • Barnett, A.1    Allsworth, J.2    Jameson, K.3    Mann, R.4
  • 23
    • 84891526739 scopus 로고    scopus 로고
    • Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus
    • Barnett AH Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013, 125:92-100.
    • (2013) Postgrad Med , vol.125 , pp. 92-100
    • Barnett, A.H.1
  • 24
    • 84883752404 scopus 로고    scopus 로고
    • New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)
    • Henry RR, Chilton R, Garvey WT New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications 2013, 27:508-518.
    • (2013) J Diabetes Complications , vol.27 , pp. 508-518
    • Henry, R.R.1    Chilton, R.2    Garvey, W.T.3
  • 25
    • 79960847840 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
    • Smith BW, Adams LA Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011, 7:456-465.
    • (2011) Nat Rev Endocrinol , vol.7 , pp. 456-465
    • Smith, B.W.1    Adams, L.A.2
  • 26
    • 84892488695 scopus 로고    scopus 로고
    • Diabetes and cancer: two diseases with obesity as a common risk factor
    • published online May 13
    • Garg SK, Maurer H, Reed K, Selagamsetty R Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2013, published online May 13. DOI:0.1111/dom.12124.
    • (2013) Diabetes Obes Metab
    • Garg, S.K.1    Maurer, H.2    Reed, K.3    Selagamsetty, R.4
  • 28
    • 33749451327 scopus 로고    scopus 로고
    • Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence
    • Lastra G, Manrique C, Sowers JR Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis 2006, 13:365-373.
    • (2006) Adv Chronic Kidney Dis , vol.13 , pp. 365-373
    • Lastra, G.1    Manrique, C.2    Sowers, J.R.3
  • 29
    • 80052341866 scopus 로고    scopus 로고
    • Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project
    • Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci 2011, 52:4416-4421.
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 4416-4421
    • Dirani, M.1    Xie, J.2    Fenwick, E.3
  • 30
    • 79955947572 scopus 로고    scopus 로고
    • Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance
    • Laitinen T, Lindström J, Eriksson J, et al. Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabet Med 2011, 28:699-704.
    • (2011) Diabet Med , vol.28 , pp. 699-704
    • Laitinen, T.1    Lindström, J.2    Eriksson, J.3
  • 31
    • 79960202841 scopus 로고    scopus 로고
    • Type 2 diabetes across generations: from pathophysiology to prevention and management
    • Nolan CJ, Damm P, Prentki M Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378:169-181.
    • (2011) Lancet , vol.378 , pp. 169-181
    • Nolan, C.J.1    Damm, P.2    Prentki, M.3
  • 32
    • 84869503599 scopus 로고    scopus 로고
    • The genetic and epigenetic basis of type 2 diabetes and obesity
    • Drong AW, Lindgren CM, McCarthy MI The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012, 92:707-715.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 707-715
    • Drong, A.W.1    Lindgren, C.M.2    McCarthy, M.I.3
  • 33
    • 84859441376 scopus 로고    scopus 로고
    • Obesity and type 2 diabetes: which patients are at risk?
    • Garber AJ Obesity and type 2 diabetes: which patients are at risk?. Diabetes Obes Metab 2012, 14:399-408.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 399-408
    • Garber, A.J.1
  • 34
    • 80052538342 scopus 로고    scopus 로고
    • Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function
    • Hectors TL, Vanparys C, van der Ven K, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia 2011, 54:1273-1290.
    • (2011) Diabetologia , vol.54 , pp. 1273-1290
    • Hectors, T.L.1    Vanparys, C.2    van der Ven, K.3
  • 35
    • 79551577263 scopus 로고    scopus 로고
    • Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes
    • Musso G, Gambino R, Cassader M Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011, 62:361-380.
    • (2011) Annu Rev Med , vol.62 , pp. 361-380
    • Musso, G.1    Gambino, R.2    Cassader, M.3
  • 36
    • 84856339193 scopus 로고    scopus 로고
    • Effects of amylin on eating and adiposity
    • Lutz TA Effects of amylin on eating and adiposity. Handb Exp Pharmacol 2012, 209:231-250.
    • (2012) Handb Exp Pharmacol , vol.209 , pp. 231-250
    • Lutz, T.A.1
  • 37
    • 84878854783 scopus 로고    scopus 로고
    • The role of leptin in the control of insulin-glucose axis
    • Amitani M, Asakawa A, Amitani H, Inui A The role of leptin in the control of insulin-glucose axis. Front Neurosci 2013, 7:51.
    • (2013) Front Neurosci , vol.7 , pp. 51
    • Amitani, M.1    Asakawa, A.2    Amitani, H.3    Inui, A.4
  • 38
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 39
    • 3343024281 scopus 로고    scopus 로고
    • Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition
    • the American Diabetes Association, the North American Association for the Study of Obesitythe North American Association for the Study of Obesity, the American Society for Clinical Nutritionthe American Society for Clinical Nutrition
    • Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004, 27:2067-2073. the American Diabetes Association, the North American Association for the Study of Obesitythe North American Association for the Study of Obesity, the American Society for Clinical Nutritionthe American Society for Clinical Nutrition.
    • (2004) Diabetes Care , vol.27 , pp. 2067-2073
    • Klein, S.1    Sheard, N.F.2    Pi-Sunyer, X.3
  • 40
    • 84874311824 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes
    • Ajala O, English P, Pinkney J Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013, 97:505-516.
    • (2013) Am J Clin Nutr , vol.97 , pp. 505-516
    • Ajala, O.1    English, P.2    Pinkney, J.3
  • 41
    • 84872743369 scopus 로고    scopus 로고
    • Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies
    • Te Morenga L, Mallard S, Mann J Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 2013, 346:e7492.
    • (2013) BMJ , vol.346
    • Te Morenga, L.1    Mallard, S.2    Mann, J.3
  • 42
    • 84855357614 scopus 로고    scopus 로고
    • The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
    • Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14:112-120.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 112-120
    • Kootte, R.S.1    Vrieze, A.2    Holleman, F.3
  • 43
    • 79955549960 scopus 로고    scopus 로고
    • Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis
    • Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011, 305:1790-1799.
    • (2011) JAMA , vol.305 , pp. 1790-1799
    • Umpierre, D.1    Ribeiro, P.A.2    Kramer, C.K.3
  • 44
    • 84873678101 scopus 로고    scopus 로고
    • The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis
    • Vissers D, Hens W, Taeymans J, Baeyens JP, Poortmans J, Van Gaal L The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One 2013, 8:e56415.
    • (2013) PLoS One , vol.8
    • Vissers, D.1    Hens, W.2    Taeymans, J.3    Baeyens, J.P.4    Poortmans, J.5    Van Gaal, L.6
  • 45
    • 77958585060 scopus 로고    scopus 로고
    • Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis
    • Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health 2010, 10:653.
    • (2010) BMC Public Health , vol.10 , pp. 653
    • Cardona-Morrell, M.1    Rychetnik, L.2    Morrell, S.L.3    Espinel, P.T.4    Bauman, A.5
  • 46
    • 21844445860 scopus 로고    scopus 로고
    • Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes
    • Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005, 2. CD004095.
    • (2005) Cochrane Database Syst Rev , vol.2 , pp. CD004095
    • Norris, S.L.1    Zhang, X.2    Avenell, A.3
  • 47
    • 84871314601 scopus 로고    scopus 로고
    • Association of an intensive lifestyle intervention with remission of type 2 diabetes
    • the Look AHEAD Research Group
    • Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012, 308:2489-2496. the Look AHEAD Research Group.
    • (2012) JAMA , vol.308 , pp. 2489-2496
    • Gregg, E.W.1    Chen, H.2    Wagenknecht, L.E.3
  • 48
    • 84891919414 scopus 로고    scopus 로고
    • Long-term drug treatment for obesity: a systematic and clinical review
    • Yanovski SZ, Yanovski JA Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014, 311:74-86.
    • (2014) JAMA , vol.311 , pp. 74-86
    • Yanovski, S.Z.1    Yanovski, J.A.2
  • 49
    • 0343963791 scopus 로고    scopus 로고
    • Antiobesity pharmacotherapy in the management of type 2 diabetes
    • Scheen AJ, Lefèbvre PJ Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000, 16:114-124.
    • (2000) Diabetes Metab Res Rev , vol.16 , pp. 114-124
    • Scheen, A.J.1    Lefèbvre, P.J.2
  • 51
    • 84880061487 scopus 로고    scopus 로고
    • New obesity agents: lorcaserin and phentermine/topiramate
    • Fleming JW, McClendon KS, Riche DM New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother 2013, 47:1007-1016.
    • (2013) Ann Pharmacother , vol.47 , pp. 1007-1016
    • Fleming, J.W.1    McClendon, K.S.2    Riche, D.M.3
  • 53
    • 84880384649 scopus 로고    scopus 로고
    • Evaluation of lorcaserin for the treatment of obesity
    • Berlie HD, Hurren KM Evaluation of lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol 2013, 9:1053-1059.
    • (2013) Expert Opin Drug Metab Toxicol , vol.9 , pp. 1053-1059
    • Berlie, H.D.1    Hurren, K.M.2
  • 54
    • 0034516930 scopus 로고    scopus 로고
    • Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
    • James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119-2125.
    • (2000) Lancet , vol.356 , pp. 2119-2125
    • James, W.P.1    Astrup, A.2    Finer, N.3
  • 55
    • 0035702916 scopus 로고    scopus 로고
    • The importance of obesity in diabetes and its treatment with sibutramine
    • Van Gaal LF, Peiffer FW The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001, 25(suppl 4):S24-S28.
    • (2001) Int J Obes Relat Metab Disord , vol.25 , pp. S24-S28
    • Van Gaal, L.F.1    Peiffer, F.W.2
  • 56
    • 15944371577 scopus 로고    scopus 로고
    • Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies
    • Vettor R, Serra R, Fabris R, Pagano C, Federspil G Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005, 28:942-949.
    • (2005) Diabetes Care , vol.28 , pp. 942-949
    • Vettor, R.1    Serra, R.2    Fabris, R.3    Pagano, C.4    Federspil, G.5
  • 57
    • 0036943785 scopus 로고    scopus 로고
    • New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat
    • Scheen AJ, Ernest P New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002, 28:437-445.
    • (2002) Diabetes Metab , vol.28 , pp. 437-445
    • Scheen, A.J.1    Ernest, P.2
  • 58
    • 77957292772 scopus 로고    scopus 로고
    • Cardiovascular risk-benefit profile of sibutramine
    • Scheen AJ Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 2010, 10:321-334.
    • (2010) Am J Cardiovasc Drugs , vol.10 , pp. 321-334
    • Scheen, A.J.1
  • 59
    • 77956284607 scopus 로고    scopus 로고
    • Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
    • the SCOUT Investigators
    • James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363:905-917. the SCOUT Investigators.
    • (2010) N Engl J Med , vol.363 , pp. 905-917
    • James, W.P.1    Caterson, I.D.2    Coutinho, W.3
  • 60
    • 84863412995 scopus 로고    scopus 로고
    • Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial
    • the SCOUT Investigators
    • Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012, 14:523-530. the SCOUT Investigators.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 523-530
    • Caterson, I.D.1    Finer, N.2    Coutinho, W.3
  • 61
    • 17144382751 scopus 로고    scopus 로고
    • Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
    • the RIO-Europe Study Group
    • Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, Grp RI-ES Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397. the RIO-Europe Study Group.
    • (2005) Lancet , vol.365 , pp. 1389-1397
    • Van Gaal, L.F.1    Rissanen, A.M.2    Scheen, A.J.3    Ziegler, O.4    Rössner, S.5    Grp, R.I.-E.S.6
  • 62
    • 41149130137 scopus 로고    scopus 로고
    • Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program
    • Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(suppl 2):S229-S240.
    • (2008) Diabetes Care , vol.31 , pp. S229-S240
    • Van Gaal, L.1    Pi-Sunyer, X.2    Després, J.P.3    McCarthy, C.4    Scheen, A.5
  • 63
    • 36048995288 scopus 로고    scopus 로고
    • Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
    • Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
    • (2007) Lancet , vol.370 , pp. 1706-1713
    • Christensen, R.1    Kristensen, P.K.2    Bartels, E.M.3    Bliddal, H.4    Astrup, A.5
  • 64
    • 77956017429 scopus 로고    scopus 로고
    • Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
    • the CRESCENDO Investigators
    • Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010, 376:517-523. the CRESCENDO Investigators.
    • (2010) Lancet , vol.376 , pp. 517-523
    • Topol, E.J.1    Bousser, M.G.2    Fox, K.A.3
  • 66
    • 1042303480 scopus 로고    scopus 로고
    • XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients
    • Torgerson JS, Hauptman J, Boldrin MN, Sjöström L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
    • (2004) Diabetes Care , vol.27 , pp. 155-161
    • Torgerson, J.S.1    Hauptman, J.2    Boldrin, M.N.3    Sjöström, L.4
  • 67
    • 61549134855 scopus 로고    scopus 로고
    • Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
    • Jacob S, Rabbia M, Meier MK, Hauptman J Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009, 11:361-371.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 361-371
    • Jacob, S.1    Rabbia, M.2    Meier, M.K.3    Hauptman, J.4
  • 68
    • 8344272013 scopus 로고    scopus 로고
    • A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
    • the OBES-002 Study Group
    • Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004, 28:1399-1410. the OBES-002 Study Group.
    • (2004) Int J Obes Relat Metab Disord , vol.28 , pp. 1399-1410
    • Wilding, J.1    Van Gaal, L.2    Rissanen, A.3    Vercruysse, F.4    Fitchet, M.5
  • 69
    • 34250842579 scopus 로고    scopus 로고
    • Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial
    • Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 2007, 31:1140-1147.
    • (2007) Int J Obes , vol.31 , pp. 1140-1147
    • Eliasson, B.1    Gudbjörnsdottir, S.2    Cederholm, J.3    Liang, Y.4    Vercruysse, F.5    Smith, U.6
  • 70
    • 84867313623 scopus 로고    scopus 로고
    • Phentermine and topiramate extended release (Qsymia™): first global approval
    • Cameron F, Whiteside G, McKeage K Phentermine and topiramate extended release (Qsymia™): first global approval. Drugs 2012, 72:2033-2042.
    • (2012) Drugs , vol.72 , pp. 2033-2042
    • Cameron, F.1    Whiteside, G.2    McKeage, K.3
  • 71
    • 78649665803 scopus 로고    scopus 로고
    • Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease
    • Bays H Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010, 8:1777-1801.
    • (2010) Expert Rev Cardiovasc Ther , vol.8 , pp. 1777-1801
    • Bays, H.1
  • 72
    • 79954561234 scopus 로고    scopus 로고
    • Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
    • Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:1341-1352.
    • (2011) Lancet , vol.377 , pp. 1341-1352
    • Gadde, K.M.1    Allison, D.B.2    Ryan, D.H.3
  • 73
    • 84856388467 scopus 로고    scopus 로고
    • Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
    • Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012, 95:297-308.
    • (2012) Am J Clin Nutr , vol.95 , pp. 297-308
    • Garvey, W.T.1    Ryan, D.H.2    Look, M.3
  • 74
    • 84897883613 scopus 로고    scopus 로고
    • Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release
    • published online Oct 8.
    • Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release. Diabetes Care 2013, published online Oct 8. 10.2337/dc13-1518.
    • (2013) Diabetes Care
    • Garvey, W.T.1    Ryan, D.H.2    Henry, R.3
  • 75
    • 84879431131 scopus 로고    scopus 로고
    • Lorcaserin: a review of its use in chronic weight management
    • Hoy SM Lorcaserin: a review of its use in chronic weight management. Drugs 2013, 73:463-473.
    • (2013) Drugs , vol.73 , pp. 463-473
    • Hoy, S.M.1
  • 76
    • 84876483004 scopus 로고    scopus 로고
    • Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
    • Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013, 14:383-392.
    • (2013) Obes Rev , vol.14 , pp. 383-392
    • Chan, E.W.1    He, Y.2    Chui, C.S.3    Wong, A.Y.4    Lau, W.C.5    Wong, I.C.6
  • 77
    • 84862869642 scopus 로고    scopus 로고
    • Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study
    • O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012, 20:1426-1436.
    • (2012) Obesity , vol.20 , pp. 1426-1436
    • O'Neil, P.M.1    Smith, S.R.2    Weissman, N.J.3
  • 79
    • 79956109928 scopus 로고    scopus 로고
    • Pramlintide and the treatment of diabetes: a review of the data since its introduction
    • Younk LM, Mikeladze M, Davis SN Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011, 12:1439-1451.
    • (2011) Expert Opin Pharmacother , vol.12 , pp. 1439-1451
    • Younk, L.M.1    Mikeladze, M.2    Davis, S.N.3
  • 80
    • 83455244389 scopus 로고    scopus 로고
    • A review of gliptins in 2011
    • Scheen AJ A review of gliptins in 2011. Expert Opin Pharmacother 2012, 13:81-99.
    • (2012) Expert Opin Pharmacother , vol.13 , pp. 81-99
    • Scheen, A.J.1
  • 81
    • 84873099484 scopus 로고    scopus 로고
    • Cardiovascular effects of gliptins
    • Scheen AJ Cardiovascular effects of gliptins. Nat Rev Cardiol 2013, 10:73-84.
    • (2013) Nat Rev Cardiol , vol.10 , pp. 73-84
    • Scheen, A.J.1
  • 82
    • 84860204551 scopus 로고    scopus 로고
    • Cardiovascular biology of the incretin system
    • Ussher JR, Drucker DJ Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
    • (2012) Endocr Rev , vol.33 , pp. 187-215
    • Ussher, J.R.1    Drucker, D.J.2
  • 83
    • 84875263303 scopus 로고    scopus 로고
    • Is there a place for incretin therapies in obesity and prediabetes?
    • Holst JJ, Deacon CF Is there a place for incretin therapies in obesity and prediabetes?. Trends Endocrinol Metab 2013, 24:145-152.
    • (2013) Trends Endocrinol Metab , vol.24 , pp. 145-152
    • Holst, J.J.1    Deacon, C.F.2
  • 84
    • 84859003663 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    • Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
    • (2012) BMJ , vol.344 , pp. d7771
    • Vilsbøll, T.1    Christensen, M.2    Junker, A.E.3    Knop, F.K.4    Gluud, L.L.5
  • 85
    • 84871138624 scopus 로고    scopus 로고
    • Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
    • Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013, 15:42-54.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 42-54
    • Niswender, K.1    Pi-Sunyer, X.2    Buse, J.3
  • 86
    • 44949134945 scopus 로고    scopus 로고
    • Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    • Van Gaal LF, Gutkin SW, Nauck MA Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. Eur J Endocrinol 2008, 158:773-784.
    • (2008) Eur J Endocrinol , vol.158 , pp. 773-784
    • Van Gaal, L.F.1    Gutkin, S.W.2    Nauck, M.A.3
  • 87
    • 84871125993 scopus 로고    scopus 로고
    • Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings
    • Holst JJ, Vilsbøll T Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013, 15:3-14.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 3-14
    • Holst, J.J.1    Vilsbøll, T.2
  • 88
    • 70350619609 scopus 로고    scopus 로고
    • Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    • the NN8022-1807 Study Group
    • Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616. the NN8022-1807 Study Group.
    • (2009) Lancet , vol.374 , pp. 1606-1616
    • Astrup, A.1    Rössner, S.2    Van Gaal, L.3
  • 89
    • 84862207266 scopus 로고    scopus 로고
    • Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    • the NN8022-1807 Investigators
    • Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012, 36:843-854. the NN8022-1807 Investigators.
    • (2012) Int J Obes , vol.36 , pp. 843-854
    • Astrup, A.1    Carraro, R.2    Finer, N.3
  • 90
    • 80052362968 scopus 로고    scopus 로고
    • Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
    • Abdul-Ghani MA, Norton L, Defronzo RA Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32:515-531.
    • (2011) Endocr Rev , vol.32 , pp. 515-531
    • Abdul-Ghani, M.A.1    Norton, L.2    Defronzo, R.A.3
  • 91
    • 84869998632 scopus 로고    scopus 로고
    • Dapagliflozin: a review of its use in type 2 diabetes mellitus
    • Plosker GL Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012, 72:2289-2312.
    • (2012) Drugs , vol.72 , pp. 2289-2312
    • Plosker, G.L.1
  • 92
    • 84877871970 scopus 로고    scopus 로고
    • Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
    • Lamos EM, Younk LM, Davis SN Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013, 9:763-775.
    • (2013) Expert Opin Drug Metab Toxicol , vol.9 , pp. 763-775
    • Lamos, E.M.1    Younk, L.M.2    Davis, S.N.3
  • 93
    • 84858020943 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
    • Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97:1020-1031.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 1020-1031
    • Bolinder, J.1    Ljunggren, Ö2    Kullberg, J.3
  • 94
    • 84864371186 scopus 로고    scopus 로고
    • Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats
    • Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity 2012, 20:1645-1652.
    • (2012) Obesity , vol.20 , pp. 1645-1652
    • Devenny, J.J.1    Godonis, H.E.2    Harvey, S.J.3    Rooney, S.4    Cullen, M.J.5    Pelleymounter, M.A.6
  • 95
    • 84860163107 scopus 로고    scopus 로고
    • Anti-obesity drugs: a review about their effects and their safety
    • Derosa G, Maffioli P Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012, 11:459-471.
    • (2012) Expert Opin Drug Saf , vol.11 , pp. 459-471
    • Derosa, G.1    Maffioli, P.2
  • 96
    • 56249110630 scopus 로고    scopus 로고
    • Hormone-based therapies in the regulation of fuel metabolism and body weight
    • Kesty NC, Roth JD, Maggs D Hormone-based therapies in the regulation of fuel metabolism and body weight. Expert Opin Biol Ther 2008, 8:1733-1747.
    • (2008) Expert Opin Biol Ther , vol.8 , pp. 1733-1747
    • Kesty, N.C.1    Roth, J.D.2    Maggs, D.3
  • 98
    • 79957480776 scopus 로고    scopus 로고
    • Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    • Katsiki N, Hatzitolios AI, Mikhailidis DP Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?. Ann Med 2011, 43:249-258.
    • (2011) Ann Med , vol.43 , pp. 249-258
    • Katsiki, N.1    Hatzitolios, A.I.2    Mikhailidis, D.P.3
  • 99
    • 77956057548 scopus 로고    scopus 로고
    • Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    • the COR-I Study Group
    • Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376:595-605. the COR-I Study Group.
    • (2010) Lancet , vol.376 , pp. 595-605
    • Greenway, F.L.1    Fujioka, K.2    Plodkowski, R.A.3
  • 100
    • 84879324574 scopus 로고    scopus 로고
    • A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
    • the COR-II Study Group
    • Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013, 21:935-943. the COR-II Study Group.
    • (2013) Obesity , vol.21 , pp. 935-943
    • Apovian, C.M.1    Aronne, L.2    Rubino, D.3
  • 101
    • 84880792594 scopus 로고    scopus 로고
    • Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
    • Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013, 15:863-866.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 863-866
    • Smith, S.R.1    Fujioka, K.2    Gupta, A.K.3
  • 103
    • 84881127469 scopus 로고    scopus 로고
    • The role of leptin in obesity and the potential for leptin replacement therapy
    • Feng H, Zheng L, Feng Z, Zhao Y, Zhang N The role of leptin in obesity and the potential for leptin replacement therapy. Endocrine 2013, 44:33-39.
    • (2013) Endocrine , vol.44 , pp. 33-39
    • Feng, H.1    Zheng, L.2    Feng, Z.3    Zhao, Y.4    Zhang, N.5
  • 104
    • 84878949822 scopus 로고    scopus 로고
    • Leptin therapy in type 2 diabetes
    • Cummings BP Leptin therapy in type 2 diabetes. Diabetes Obes Metab 2013, 15:607-612.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 607-612
    • Cummings, B.P.1
  • 105
    • 84879467338 scopus 로고    scopus 로고
    • Metreleptin: first global approval
    • Chou K, Perry CM Metreleptin: first global approval. Drugs 2013, 73:989-997.
    • (2013) Drugs , vol.73 , pp. 989-997
    • Chou, K.1    Perry, C.M.2
  • 106
    • 79959409408 scopus 로고    scopus 로고
    • Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance
    • Moon HS, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011, 60:1647-1656.
    • (2011) Diabetes , vol.60 , pp. 1647-1656
    • Moon, H.S.1    Matarese, G.2    Brennan, A.M.3
  • 107
    • 80052850811 scopus 로고    scopus 로고
    • Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs
    • Grasso P Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs. Recent Pat Endocr Metab Immune Drug Discov 2011, 5:163-175.
    • (2011) Recent Pat Endocr Metab Immune Drug Discov , vol.5 , pp. 163-175
    • Grasso, P.1
  • 109
    • 69749086148 scopus 로고    scopus 로고
    • Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy
    • Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009, 17:1736-1743.
    • (2009) Obesity , vol.17 , pp. 1736-1743
    • Ravussin, E.1    Smith, S.R.2    Mitchell, J.A.3
  • 110
    • 74249091684 scopus 로고    scopus 로고
    • It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development
    • Chan JL, Roth JD, Weyer C It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 2009, 57:777-783.
    • (2009) J Investig Med , vol.57 , pp. 777-783
    • Chan, J.L.1    Roth, J.D.2    Weyer, C.3
  • 111
    • 80555135931 scopus 로고    scopus 로고
    • Novel strategy for the use of leptin for obesity therapy
    • Tam CS, Lecoultre V, Ravussin E Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011, 11:1677-1685.
    • (2011) Expert Opin Biol Ther , vol.11 , pp. 1677-1685
    • Tam, C.S.1    Lecoultre, V.2    Ravussin, E.3
  • 112
    • 84859733684 scopus 로고    scopus 로고
    • GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
    • Roth JD, Erickson MR, Chen S, Parkes DG GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol 2012, 166:121-136.
    • (2012) Br J Pharmacol , vol.166 , pp. 121-136
    • Roth, J.D.1    Erickson, M.R.2    Chen, S.3    Parkes, D.G.4
  • 113
    • 84879414291 scopus 로고    scopus 로고
    • Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
    • Sadry SA, Drucker DJ Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 2013, 9:425-433.
    • (2013) Nat Rev Endocrinol , vol.9 , pp. 425-433
    • Sadry, S.A.1    Drucker, D.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.